Amphastar Pharmaceuticals Total Liabilities 2012-2024 | AMPH

Amphastar Pharmaceuticals total liabilities from 2012 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Amphastar Pharmaceuticals Annual Total Liabilities
(Millions of US $)
2023 $873
2022 $213
2021 $226
2020 $183
2019 $159
2018 $149
2017 $117
2016 $98
2015 $95
2014 $108
2013 $87
2012 $84
2011 $0
2009 $141
Amphastar Pharmaceuticals Quarterly Total Liabilities
(Millions of US $)
2024-09-30 $818
2024-06-30 $778
2024-03-31 $902
2023-12-31 $873
2023-09-30 $949
2023-06-30 $789
2023-03-31 $225
2022-12-31 $213
2022-09-30 $222
2022-06-30 $224
2022-03-31 $237
2021-12-31 $226
2021-09-30 $222
2021-06-30 $199
2021-03-31 $195
2020-12-31 $183
2020-09-30 $163
2020-06-30 $158
2020-03-31 $149
2019-12-31 $159
2019-09-30 $152
2019-06-30 $169
2019-03-31 $164
2018-12-31 $149
2018-09-30 $139
2018-06-30 $131
2018-03-31 $123
2017-12-31 $117
2017-09-30 $107
2017-06-30 $111
2017-03-31 $110
2016-12-31 $98
2016-09-30 $100
2016-06-30 $101
2016-03-31 $98
2015-12-31 $95
2015-09-30 $111
2015-06-30 $114
2015-03-31 $117
2014-12-31 $108
2014-09-30 $118
2014-06-30 $110
2014-03-31 $94
2013-12-31 $87
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $84
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.186B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00